Efficacy of HA330 Hemoperfusion in Critically Ill Patients with Severe COVID-19

Not Applicable

• Conditions: COVID- 19ARDS; 19; ARDS; Pneumonia; Hemoadsorption; IL- 6

• Registration Number: TCTR20200409006
• Lead Sponsor: Excellence Center for Critical Care Nephrology, King Chulalongkorn Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-09
• Study Completion: 2021-05-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 206

Inclusion Criteria

1. Age ≥18 years
2. Diagnosed with COVID-19 by RT-PCR with ARDS
3. Admitted to intensive care unit
4. serum IL-6 ≥400 pg/m

Exclusion Criteria

1. Expected death within 24 hours
2. Pregnancy
3. Platelet count <30,000/uL
4. Terminally ill with DNI/DNR
5. History of allergy to HA330 filter
6. Coagulopathy uncontrolled within 24 hours
7. white blood cell count <500/uL
8. History of organ transplant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
28-day mortality day 28 after enrollment status of patient (alive/dead)

Secondary Outcome Measures

Name	Time	Method
clinical improvement day 1-7, 14, 21, 28 PF ratio, ventilatory status,ventilator free day day 28 days of being alive without ventilator until day 28 after enrollement,length of ICU stay day of hospital discharge days of ICU stay,length of hospital stay day of hospital discharge days of hospital stay,IL-6 level day 1, 3, 5, 7, 14, 21, 28 ECLIA, pg/m